Torre, Gross and Townsend named to Medical Advertising Hall of Fame

Share this article:
The Medical Advertising Hall of Fame announced that it would induct Joe Torre, Alan Gross and Jane Townsend at its February 8 awards dinner.

Gross and Townsend, of Gross Townsend Frank Hoffman (now part of ghg) fame, are husband and wife. They met at ER Squibb & Sons – she a journalist-turned copywriter, he a sales rep with degrees in microbiology. Gross became director of advertising at Squibb, and Townsend moved on to stints at Kallir Phillips Ross and Shaller Rubin before the two, now married, launched Gross Townsend Frank Hoffman in 1978. She became, in the process, the first female partner in a major healthcare agency and mentored a generation of female execs in healthcare advertising. Gross and Townsend sold the shop to Grey Advertising in 1986 and retired in 1993.

Joe Torre, of Torre Lazur fame, started out as a pharmacist before moving to Roche, where he worked in sales, marketing research and marketing. He joined Healthmark Communications as an account supervisor in 1977 and two years later launched Salthouse Torre Ferrante, which later became Torre Lazur Healthcare Group, which he positioned as “The Launch Agency.” He sold the shop to McCann Worldgroup in 1996, foreseeing the importance of global reach, and built an international network of agencies with 50 offices worldwide before retiring this past January.

The Medical Advertising Hall of Fame Annual Awards Dinner will be held Tuesday, February 8, at the Pierre Hotel. Tickets go on sale November 12 at the MAHF website.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...